U.K. Atrial Fibrillation Devices Market: Segmented: By Device Type (Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices), By Disorder Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Permanent Atrial Fibrillation, Others Atrial Fibrillation ), By End-User (Hospitals, Cardiac Labs, Ambulatory Surgical Centers, Others), And Region – Analysis of Market Size, Share & Trends For 2019–2021 And Forecasts To 2031
![](/report_cover/11410/uk-atrial-fibrillation-devices-market-segmented-by-device-type-by-disorder-type-by-end-user-n-region-analysis-of-market-size-share-trends-4_en.gif)
[ 170 + Pages Research Report ] U.K. Atrial Fibrillation Devices Market to surpass USD 2.063.9 million by 2031 from USD 706.1 million in 2021 at a CAGR of 11.3% in the coming years, i.e., 2021-2031.
Product Overview
Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but the most common ones associated with it are palpitations, fainting, congestive chest pain, or failure of the heart. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the P wave and an irregular rate of ventricular contractions. These irregularities in the regular cardio-electric impulses of the sino-atrial node are the result of interference from chaotic electric impulses generated from the roots of pulmonary veins consequently leading to the conduction of an irregular heartbeat.
Market Highlights
U.K. Atrial Fibrillation Devices Market is expected to project a notable CAGR of 11.3% in 2031.
In the U.K. many companies have increased their investment in research and development to innovate the existing AF devices and integrate AI-enabled solutions. R&D in atrial fibrillation is expected to offer lucrative growth opportunities for players in the U.K. atrial fibrillation market.
U.K. Atrial Fibrillation Devices Market: Segments
Therapeutic and Surgical Devices segment to grow with the highest CAGR during 2021-31
Based on Device Type, U.K. Atrial Fibrillation Devices Market is fragmented into Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices. The therapeutic and Surgical Devices segment dominates the market attributed to growing demands for ablation catheters for treating AF. This segment is also expected to witness the highest growth during the forecast period. Among the therapeutic and surgical devices, the Cardiac Rhythm Management Devices segment is the fastest-growing segment attributed to the increasing focus on early diagnosis.
Persistent Atrial Fibrillation segment to grow with the highest CAGR during 2021-31
The U.K. Atrial Fibrillation Devices Market is classified based on Disorder Type into Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Permanent Atrial Fibrillation, Others Atrial Fibrillation. The persistent Atrial Fibrillation segment accounted for the largest market share of the U.K. Atrial Fibrillation Devices market.
Market Dynamics
Drivers
Growing Adoption Of Closure Devices
The rising number of patients suffering from atrial fibrillation (AF) in the U.K. is the major factor expected to propel the growth of the market. In addition, the rising cases are also resulting in increasing demand for left atrial appendage (LAA) closure devices to treat patients. The governments are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020.
Increase In Prevalence Of Atrial Fibrillation In Geriatric Population
The increasing geriatric population with complications in the heart is the major factor driving the market. According to the Centers for Disease Control and Prevention (CDC), approximately 2 percent of people younger than 65 years old have AFib, while about 9 percent of people ages 65 and older have it.
Restraint
High Cost of U.K. Atrial Fibrillation Devices
The high price factor will continue to hinder the atrial fibrillation devices' market value during the forecast timeframe and impede the adoption rates in underdeveloped and few developing countries.
U.K. Atrial Fibrillation Devices Market: Key Players
Abbott
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Boston Scientific Corporation,
Biotronik,
Cardinal Health,
GE Healthcare,
Medtronic Plc,
Siemens Healthineers AG,
W. L. Gore & Associates, Inc.,
Hansen Medical Inc,
Cardiofocus Inc
Other Prominent Players
U.K. Atrial Fibrillation Devices Market: Regions
U.K. Atrial Fibrillation Devices market is segmented based on regional analysis into four major regions: England, Northern Ireland, Scotland, and Wales. England is among the top revenue generator for atrial fibrillation devices. The high incidence rate of cardiovascular diseases in the region and development of the strong technologies in the country has witnessed significant growth for the product. The country also has a strong number of players present in the country across the atrial fibrillation value chain Another key country in the region is Northern Ireland, Scotland, and Wales. Focus on the improved treatment producers with implementation of the AI in Atrial fibrillations, supporting the product growth.
Impact of Covid-19 on U.K. Atrial Fibrillation Devices Market
The market of AF devices is expected to witness healthy growth in 2022 post-COVID-19 outbreak. This can be attributed to increasing awareness among people about the importance of AF devices. This factor will boost the market growth in the forecast years. The rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the market. In addition, the rising cases of COVID-19 are resulting in increasing demand for left atrial appendage (LAA) closure devices for treating the patients This is helping the market to witness progressive growth in the pandemic crisis.
U.K. Atrial Fibrillation Devices Market is further segmented by region into:
England Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Northern Ireland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Scotland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Wales Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
U.K. Atrial Fibrillation Devices Market report also contains an analysis on:
U.K. Atrial Fibrillation Devices Market Segments:
By Device Type
Diagnostic and Monitoring Devices
Therapeutic and Surgical Devices
By Disorder Type
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Permanent Atrial Fibrillation
Others Atrial Fibrillation
By End User
Hospitals
Cardiac Labs
Ambulatory Surgical Centers
Others
U.K. Atrial Fibrillation Devices Market Dynamics
the U.K. Atrial Fibrillation Devices Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
U.K. Atrial Fibrillation Devices Market Report Scope and Segmentation
Report Attribute Details
The market size value in 2021 USD 706.1 million
The revenue forecast in 2031 USD 2.063.9 million
Growth Rate CAGR of 11.3% from 2021 to 2031
The base year for estimation 2020
Quantitative units Revenue in USD million and CAGR from 2021 to 2031
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Device Type, Disorder Type, End-User and Region
Regional scope England, Northern Ireland, Scotland, and Wales
Key companies profiled Abbott, Boston Scientific Corporation, Biotronik, Cardinal Health, GEHealthcare, Medtronic Plc, Siemens Healthineers AG, W. L. Gore & Associates, Inc., Hansen Medical Inc, Cardio focus, and Other Prominent Players
Product Overview
Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but the most common ones associated with it are palpitations, fainting, congestive chest pain, or failure of the heart. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the P wave and an irregular rate of ventricular contractions. These irregularities in the regular cardio-electric impulses of the sino-atrial node are the result of interference from chaotic electric impulses generated from the roots of pulmonary veins consequently leading to the conduction of an irregular heartbeat.
Market Highlights
U.K. Atrial Fibrillation Devices Market is expected to project a notable CAGR of 11.3% in 2031.
In the U.K. many companies have increased their investment in research and development to innovate the existing AF devices and integrate AI-enabled solutions. R&D in atrial fibrillation is expected to offer lucrative growth opportunities for players in the U.K. atrial fibrillation market.
U.K. Atrial Fibrillation Devices Market: Segments
Therapeutic and Surgical Devices segment to grow with the highest CAGR during 2021-31
Based on Device Type, U.K. Atrial Fibrillation Devices Market is fragmented into Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices. The therapeutic and Surgical Devices segment dominates the market attributed to growing demands for ablation catheters for treating AF. This segment is also expected to witness the highest growth during the forecast period. Among the therapeutic and surgical devices, the Cardiac Rhythm Management Devices segment is the fastest-growing segment attributed to the increasing focus on early diagnosis.
Persistent Atrial Fibrillation segment to grow with the highest CAGR during 2021-31
The U.K. Atrial Fibrillation Devices Market is classified based on Disorder Type into Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Permanent Atrial Fibrillation, Others Atrial Fibrillation. The persistent Atrial Fibrillation segment accounted for the largest market share of the U.K. Atrial Fibrillation Devices market.
Market Dynamics
Drivers
Growing Adoption Of Closure Devices
The rising number of patients suffering from atrial fibrillation (AF) in the U.K. is the major factor expected to propel the growth of the market. In addition, the rising cases are also resulting in increasing demand for left atrial appendage (LAA) closure devices to treat patients. The governments are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020.
Increase In Prevalence Of Atrial Fibrillation In Geriatric Population
The increasing geriatric population with complications in the heart is the major factor driving the market. According to the Centers for Disease Control and Prevention (CDC), approximately 2 percent of people younger than 65 years old have AFib, while about 9 percent of people ages 65 and older have it.
Restraint
High Cost of U.K. Atrial Fibrillation Devices
The high price factor will continue to hinder the atrial fibrillation devices' market value during the forecast timeframe and impede the adoption rates in underdeveloped and few developing countries.
U.K. Atrial Fibrillation Devices Market: Key Players
Abbott
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Boston Scientific Corporation,
Biotronik,
Cardinal Health,
GE Healthcare,
Medtronic Plc,
Siemens Healthineers AG,
W. L. Gore & Associates, Inc.,
Hansen Medical Inc,
Cardiofocus Inc
Other Prominent Players
U.K. Atrial Fibrillation Devices Market: Regions
U.K. Atrial Fibrillation Devices market is segmented based on regional analysis into four major regions: England, Northern Ireland, Scotland, and Wales. England is among the top revenue generator for atrial fibrillation devices. The high incidence rate of cardiovascular diseases in the region and development of the strong technologies in the country has witnessed significant growth for the product. The country also has a strong number of players present in the country across the atrial fibrillation value chain Another key country in the region is Northern Ireland, Scotland, and Wales. Focus on the improved treatment producers with implementation of the AI in Atrial fibrillations, supporting the product growth.
Impact of Covid-19 on U.K. Atrial Fibrillation Devices Market
The market of AF devices is expected to witness healthy growth in 2022 post-COVID-19 outbreak. This can be attributed to increasing awareness among people about the importance of AF devices. This factor will boost the market growth in the forecast years. The rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the market. In addition, the rising cases of COVID-19 are resulting in increasing demand for left atrial appendage (LAA) closure devices for treating the patients This is helping the market to witness progressive growth in the pandemic crisis.
U.K. Atrial Fibrillation Devices Market is further segmented by region into:
England Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Northern Ireland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Scotland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Wales Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
U.K. Atrial Fibrillation Devices Market report also contains an analysis on:
U.K. Atrial Fibrillation Devices Market Segments:
By Device Type
Diagnostic and Monitoring Devices
Therapeutic and Surgical Devices
By Disorder Type
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Permanent Atrial Fibrillation
Others Atrial Fibrillation
By End User
Hospitals
Cardiac Labs
Ambulatory Surgical Centers
Others
U.K. Atrial Fibrillation Devices Market Dynamics
the U.K. Atrial Fibrillation Devices Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
U.K. Atrial Fibrillation Devices Market Report Scope and Segmentation
Report Attribute Details
The market size value in 2021 USD 706.1 million
The revenue forecast in 2031 USD 2.063.9 million
Growth Rate CAGR of 11.3% from 2021 to 2031
The base year for estimation 2020
Quantitative units Revenue in USD million and CAGR from 2021 to 2031
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Device Type, Disorder Type, End-User and Region
Regional scope England, Northern Ireland, Scotland, and Wales
Key companies profiled Abbott, Boston Scientific Corporation, Biotronik, Cardinal Health, GEHealthcare, Medtronic Plc, Siemens Healthineers AG, W. L. Gore & Associates, Inc., Hansen Medical Inc, Cardio focus, and Other Prominent Players
1. EXECUTIVE SUMMARY
2. U.K. ATRIAL FIBRILLATION DEVICES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. U.K. ATRIAL FIBRILLATION DEVICES MARKET ANALYSIS
10.1. Porter Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. U.K. ATRIAL FIBRILLATION DEVICES MARKET
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12. U.K. ATRIAL FIBRILLATION DEVICES MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. England, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Northern Ireland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Scotland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Wales, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Device Type: Market Share (2020-2031F)
12.2.1. Diagnostic and Monitoring Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Therapeutic and Surgical Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Disorder Type: Market Share (2020-2031F)
12.3.1. Paroxysmal Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. Persistent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Permanent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.4. Others Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By End-User: Market Share (2020-2031F)
12.4.1. Hospitals, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Cardiac Labs, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Ambulatory Surgical Centers, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13. COMPANY PROFILE
13.1. Abbott,
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Boston Scientific Corporation,
13.3. Biotronik,
13.4. Cardinal Health,
13.5. GEHealthcare,
13.6. Medtronic Plc,
13.7. Siemens Healthineers AG,
13.8. W. L. Gore & Associates, Inc.,
13.9. Hansen Medical Inc,
13.10. Cardio focus.
13.11. Other Prominent Players
14. CONSULTANT RECOMMENDATION
14.1.1. The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable
2. U.K. ATRIAL FIBRILLATION DEVICES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. U.K. ATRIAL FIBRILLATION DEVICES MARKET ANALYSIS
10.1. Porter Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. U.K. ATRIAL FIBRILLATION DEVICES MARKET
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12. U.K. ATRIAL FIBRILLATION DEVICES MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. England, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Northern Ireland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Scotland, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Wales, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Device Type: Market Share (2020-2031F)
12.2.1. Diagnostic and Monitoring Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Therapeutic and Surgical Devices, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3. By Disorder Type: Market Share (2020-2031F)
12.3.1. Paroxysmal Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.2. Persistent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.3. Permanent Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.3.4. Others Atrial Fibrillation, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4. By End-User: Market Share (2020-2031F)
12.4.1. Hospitals, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.2. Cardiac Labs, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.3. Ambulatory Surgical Centers, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.4.4. Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13. COMPANY PROFILE
13.1. Abbott,
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Boston Scientific Corporation,
13.3. Biotronik,
13.4. Cardinal Health,
13.5. GEHealthcare,
13.6. Medtronic Plc,
13.7. Siemens Healthineers AG,
13.8. W. L. Gore & Associates, Inc.,
13.9. Hansen Medical Inc,
13.10. Cardio focus.
13.11. Other Prominent Players
14. CONSULTANT RECOMMENDATION
14.1.1. The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable